142 related articles for article (PubMed ID: 25645675)
1. Phosphoinositide-dependent protein kinase 1 (PDK1) mediates potent inhibitory effects on eosinophils.
Sturm EM; Parzmair GP; Radnai B; Frei RB; Sturm GJ; Hammer A; Schuligoi R; Lippe IT; Heinemann A
Eur J Immunol; 2015 May; 45(5):1548-59. PubMed ID: 25645675
[TBL] [Abstract][Full Text] [Related]
2. EP4 receptor stimulation down-regulates human eosinophil function.
Luschnig-Schratl P; Sturm EM; Konya V; Philipose S; Marsche G; Fröhlich E; Samberger C; Lang-Loidolt D; Gattenlöhner S; Lippe IT; Peskar BA; Schuligoi R; Heinemann A
Cell Mol Life Sci; 2011 Nov; 68(21):3573-87. PubMed ID: 21365278
[TBL] [Abstract][Full Text] [Related]
3. Prostaglandin E2 stimulates normal bronchial epithelial cell growth through induction of c-Jun and PDK1, a kinase implicated in oncogenesis.
Fan Y; Wang Y; Wang K
Respir Res; 2015 Dec; 16():149. PubMed ID: 26684827
[TBL] [Abstract][Full Text] [Related]
4. Interaction of eosinophils with endothelial cells is modulated by prostaglandin EP4 receptors.
Konya V; Philipose S; Bálint Z; Olschewski A; Marsche G; Sturm EM; Schicho R; Peskar BA; Schuligoi R; Heinemann A
Eur J Immunol; 2011 Aug; 41(8):2379-89. PubMed ID: 21681739
[TBL] [Abstract][Full Text] [Related]
5. PDK1 in NF-κB signaling is a target of Xanthium strumarium methanolic extract-mediated anti-inflammatory activities.
Hossen MJ; Cho JY; Kim D
J Ethnopharmacol; 2016 Aug; 190():251-60. PubMed ID: 27286918
[TBL] [Abstract][Full Text] [Related]
6. Involvement of EP2 and EP4 Receptors in Eosinophilic Esophagitis: A Pilot Study.
Durchschein F; Eherer A; Grill M; Sturm EM; Pommer V; Langner C; Högenauer C; Schicho R
Dig Dis Sci; 2019 Oct; 64(10):2806-2814. PubMed ID: 30989466
[TBL] [Abstract][Full Text] [Related]
7. Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1.
Najafov A; Sommer EM; Axten JM; Deyoung MP; Alessi DR
Biochem J; 2011 Jan; 433(2):357-69. PubMed ID: 21087210
[TBL] [Abstract][Full Text] [Related]
8. Prostaglandin E2-Induced COX-2 Expressions via EP2 and EP4 Signaling Pathways in Human LoVo Colon Cancer Cells.
Hsu HH; Lin YM; Shen CY; Shibu MA; Li SY; Chang SH; Lin CC; Chen RJ; Viswanadha VP; Shih HN; Huang CY
Int J Mol Sci; 2017 May; 18(6):. PubMed ID: 28587064
[TBL] [Abstract][Full Text] [Related]
9. Prostaglandin E
Bryson TD; Ross J; Peterson E; Harding P
Prostaglandins Other Lipid Mediat; 2019 Oct; 144():106349. PubMed ID: 31229524
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of airway smooth muscle cell migration by E-prostanoid receptor subtypes.
Aso H; Ito S; Mori A; Suganuma N; Morioka M; Takahara N; Kondo M; Hasegawa Y
Am J Respir Cell Mol Biol; 2013 Mar; 48(3):322-9. PubMed ID: 23221043
[TBL] [Abstract][Full Text] [Related]
11. Prostaglandin E2 inhibits eosinophil trafficking through E-prostanoid 2 receptors.
Sturm EM; Schratl P; Schuligoi R; Konya V; Sturm GJ; Lippe IT; Peskar BA; Heinemann A
J Immunol; 2008 Nov; 181(10):7273-83. PubMed ID: 18981149
[TBL] [Abstract][Full Text] [Related]
12. PDK1 governs thromboxane generation and thrombosis in platelets by regulating activation of Raf1 in the MAPK pathway.
Manne BK; Münzer P; Badolia R; Walker-Allgaier B; Campbell RA; Middleton E; Weyrich AS; Kunapuli SP; Borst O; Rondina MT
J Thromb Haemost; 2018 Jun; 16(6):1211-1225. PubMed ID: 29575487
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E2 enhances interleukin-8 production via EP4 receptor in human pulmonary microvascular endothelial cells.
Aso H; Ito S; Mori A; Morioka M; Suganuma N; Kondo M; Imaizumi K; Hasegawa Y
Am J Physiol Lung Cell Mol Physiol; 2012 Jan; 302(2):L266-73. PubMed ID: 22080750
[TBL] [Abstract][Full Text] [Related]
14. Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer.
Emmanouilidi A; Fyffe CA; Ferro R; Edling CE; Capone E; Sestito S; Rapposelli S; Lattanzio R; Iacobelli S; Sala G; Maffucci T; Falasca M
J Exp Clin Cancer Res; 2019 May; 38(1):191. PubMed ID: 31088502
[TBL] [Abstract][Full Text] [Related]
15. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
Zhang X; Zhong S
Anticancer Agents Med Chem; 2020; 20(7):828-833. PubMed ID: 32188393
[TBL] [Abstract][Full Text] [Related]
16. Altered inhibitory function of the E-type prostanoid receptor 4 in eosinophils and monocytes from aspirin-intolerant patients.
Luschnig P; Frei R; Lang-Loidolt D; Rozsasi A; Tomazic PV; Lippe IT; Schuligoi R; Heinemann A
Pharmacology; 2014; 94(5-6):280-6. PubMed ID: 25531811
[TBL] [Abstract][Full Text] [Related]
17. Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model.
Parida S; Parekh A; Dey G; Ghosh SC; Mandal M
Cancer Biol Ther; 2015; 16(6):922-32. PubMed ID: 25894216
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E2-stimulated prostanoid EP4 receptors induce prolonged de novo prostaglandin E2 synthesis through biphasic phosphorylation of extracellular signal-regulated kinases mediated by activation of protein kinase A in HCA-7 human colon cancer cells.
Fujino H; Seira N; Kurata N; Araki Y; Nakamura H; Regan JW; Murayama T
Eur J Pharmacol; 2015 Dec; 768():149-59. PubMed ID: 26518053
[TBL] [Abstract][Full Text] [Related]
19. PDK1 is a potential therapeutic target against angiosarcoma cells.
Wada M; Horinaka M; Yasuda S; Masuzawa M; Sakai T; Katoh N
J Dermatol Sci; 2015 Apr; 78(1):44-50. PubMed ID: 25726712
[TBL] [Abstract][Full Text] [Related]
20. Modulation of PI3K/PTEN Pathway Does Not Affect Catalytic Activity of PDK1 in Jurkat Cells.
Yang KJ; Piao L; Shin S; Shin SY; Li Y; Lee H; Tran Q; Park J; Hong S; Brazil DP; Hemmings BA; Kim SH; Park J
Anticancer Res; 2017 Oct; 37(10):5415-5423. PubMed ID: 28982851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
